SEC Suspends BioCurex Trading, Questions Firm’s Regulatory Claims
This article was originally published in The Gray Sheet
Executive Summary
Press releases claiming "FDA-approved" status for BioCurex' Class I Histo-RECAF alpha-fetoprotein (AFP) tissue staining test played a role in SEC's decision to halt trading of the company's stock April 8